Superior Ophthalmic Vein Congestion in Thyroid Eye Disease: Assessment With 3D T1 ‐Weighted Imaging and Association With Intravenous Glucocorticoid Therapy Outcomes

Authors:

Abstract
Background: 3D T1 may assess the superior ophthalmic vein (SOV) congestion, yet its role in the intravenous glucocorticoid (IVGC) therapy remains unclear. Purpose: To evaluate SOV congestion by 3D T1 in thyroid eye disease (TED) and explore its correlation with IVGC therapeutic response. Study Type: Retrospective. Subjects: One hundred thirty‐three TED patients, classified as 80 IVGC responders (45.7 ± 10.9 years, 32 males) and 53 non‐responders (47.6 ± 9.7 years, 23 males); 290 healthy controls (HCs) (47.9 ± 16.4 years, 145 males). Field Strength/Sequence: 3 T; 3D T1‐weighted spoiled gradient‐recalled echo, T2 iterative decomposition of water and fat with echo asymmetric and least‐squares estimation, and fat‐suppressed (FS) T2 mapping. Assessment: The SOV diameter (mm), along with the volume ratio, FS T2 relaxation time (T2RT [ms]), and water fraction (WF [%]) of the extraocular muscles (EOMs) and orbital fat (OF) were manually measured. Statistical Tests: Student's t ‐test, Mann–Whitney U test, one‐way analysis of variance, interclass correlation coefficient, and correlation analysis. p < 0.05 defined statistical significance. Results: TED patients presented significantly larger SOV diameters than HCs (2.21 ± 0.45 vs. 1.72 ± 0.26). Among them, the responsive group had significantly larger baseline SOV diameters (2.26 ± 0.49 vs. 2.15 ± 0.39), along with higher FS T2RT (71.30 ± 14.32 vs. 67.65 ± 13.33) and WF (79.31 ± 13.68 vs. 75.17 ± 14.47) in the EOMs compared to the nonresponsive group. The SOV diameter demonstrated moderate‐to‐good positive correlations with FS T2RT ( r = 0.59) and WF ( r = 0.67) in responders. Following IVGC therapy, a significant reduction in SOV diameter was observed exclusively in the responsive group (2.26 ± 0.49 vs. 1.98 ± 0.47). Data Conclusion: Patients exhibiting more severe SOV congestion showed a better response to IVGC therapy, potentially due to an enhanced inflammatory state in the EOMs. Evidence Level: 4. Technical Efficacy: Stage 4.
Funding Information
  • National Natural Science Foundation of China (82471967)

This publication has 17 references indexed in Scilit: